ArticleClinical rheumatology2025
The effect of cold atmospheric plasma on inflammatory and joint destructive factors in osteoarthritic fibroblast-like synoviocytes.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cold Atmospheric Plasma as a Potential Disease-Modifying Therapy for Osteoarthritis.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionActivated fibroblast-like synoviocytes (FLSs) are associated with the clinical symptoms of osteoarthritis (OA), causing inflammation and joint destruction, and play a role in disease progression. Cold atmospheric plasma (CAP) is a promising approach for cancer treatment, and its anti-inflammatory properties have recently been demonstrated in some inflammatory disorders. This study aimed to determine the effects of CAP produced by an argon plasma jet device on osteoarthritic fibroblast-like synoviocytes (OA-FLS).
methodsFLS cells were isolated from synovial tissues of patients with osteoarthritis. OA-FLS cells were cultured and directly exposed to CAP. Cell viability and lipid peroxidation were evaluated using MMT and MDA assays, respectively. Real-time PCR and ELISA were used to assess the inflammatory status and destructive factors in OA-FLS.
resultsThe findings showed that CAP exerted cytotoxic effects on OA-FLS. In addition, CAP treatment decreased IL-6 production in OA-FLS cells, while the expression of NF-κB and production of destructive factors, such as receptor activator of nuclear factor kappa-B ligand (RANKL) and matrix metalloproteinases-3 (MMP-3), were comparable in the CAP and untreated control groups.
conclusionThis research concluded that CAP reduces the viability of OA-FLS cells. However, its limited impact on key inflammatory and bone and cartilage destructive factors suggests that CAP alone may not be an effective treatment for joint damage in osteoarthritis. Given the lower inflammatory profile of OA compared to RA, further research is needed to explore combination therapies or alternative approaches to enhance CAP's therapeutic potential. Key Points • Cold atmospheric plasma (CAP) is a promising approach for alleviating inflammation. • CAP decreased cell viability in osteoarthritic fibroblast-like synoviocytes (OA-FLS). • CAP treatment decreased IL-6 production in OA-FLS cells.
Indexed as
Identifiers
40858880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.